Indeed, therapeutic approaches designed to suppress AR signaling in prostate cancer cells, mainly through inhibition of androgen biosynthesis by luteinizing hormone-releasing hormone (LHRH) agonist/antagonist, or through the use of receptor antagonists (antiandrogen drugs)—all these under the name of ADT—have been the main available weapons against metastatic prostate cancer for decades [12]. The gene discussed is AR; the disease is metastatic prostate carcinoma.